CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• "Moderate Buy" consensus from nine analysts (seven buys, one hold, one sell) with an average 12‑month price target of $13.31.
• CryoPort missed quarterly EPS at ($0.21) versus ($0.19) expected but beat revenue estimates with $45.45M versus $42.92M, and analysts project full‑year EPS of about -0.99.
• Shares opened at $10.17 (52‑week range $5.21–$11.45) with a market cap near $507M, and insiders sold roughly 59,939 shares over the past three months while retaining about 10% ownership.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) has earned an average rating of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $13.3125.

CYRX has been the subject of several research analyst reports. Weiss Ratings reissued a "sell (d+)" rating on shares of CryoPort in a research report on Friday, March 27th. Craig Hallum initiated coverage on CryoPort in a research report on Monday, March 30th. They set a "buy" rating and a $15.00 price objective for the company. Wall Street Zen cut CryoPort from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Finally, Needham & Company LLC boosted their price objective on CryoPort from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th.

CryoPort Stock Performance

CryoPort stock opened at $10.17 on Friday. CryoPort has a 52 week low of $5.21 and a 52 week high of $11.45. The firm has a market capitalization of $507.04 million, a PE ratio of 7.70 and a beta of 1.68. The business's 50-day simple moving average is $8.55 and its 200-day simple moving average is $9.28.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The business had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. Research analysts forecast that CryoPort will post -0.99 earnings per share for the current year.

Insider Activity at CryoPort

In related news, CFO Robert Stefanovich sold 38,700 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $7.76, for a total transaction of $300,312.00. Following the transaction, the chief financial officer directly owned 255,701 shares in the company, valued at $1,984,239.76. The trade was a 13.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jerrell Shelton sold 7,918 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the transaction, the chief executive officer owned 1,054,501 shares in the company, valued at $8,436,008. This represents a 0.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 59,939 shares of company stock worth $471,183 over the last three months. Company insiders own 10.00% of the company's stock.

Institutional Investors Weigh In On CryoPort

Large investors have recently modified their holdings of the stock. Basepoint Wealth LLC bought a new stake in shares of CryoPort in the 4th quarter valued at approximately $34,000. Tower Research Capital LLC TRC grew its position in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. Whittier Trust Co. of Nevada Inc. bought a new stake in CryoPort during the 3rd quarter worth approximately $53,000. AlphaQuest LLC bought a new stake in CryoPort during the 3rd quarter worth approximately $79,000. Finally, Creative Planning bought a new stake in CryoPort during the 2nd quarter worth approximately $96,000. 92.90% of the stock is currently owned by institutional investors.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.